NCT03648801View on ClinicalTrials.gov

A Post-marketing Surveillance to Assess Safety and Efficacy of Telostop Plus Tab.

UnknownOBSERVATIONAL
Enrollment

600

Participants

Timeline

Start Date

September 30, 2018

Primary Completion Date

May 31, 2024

Study Completion Date

August 31, 2024

Conditions
Hypertension, Dyslipidemia
Sponsors
All Listed Sponsors
lead

IlDong Pharmaceutical Co Ltd

INDUSTRY

NCT03648801 - A Post-marketing Surveillance to Assess Safety and Efficacy of Telostop Plus Tab. | Biotech Hunter | Biotech Hunter